Takanori Takebe

Takanori Takebe

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Takanori Takebe

Graduate School of Medicine, and Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), the University of Osaka 1 Department of Genome Biology Suita, Osaka 565-0871

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2013 in Nature
Verified
Journal Article
Closed access
PDF file
TTTakanori Takebe
Takanori Takebe
KSKeisuke Sekine
Keisuke Sekine
MEMasahiro Enomura
Masahiro Enomura
HKHiroyuki Koike
Hiroyuki Koike
MKMasaki Kimura
Masaki Kimura
HTHideki Taniguchi
Hideki Taniguchi

14 June 2017 in Nature
Verified
Journal Article
Closed access
JCJ. Gray Camp
J. Gray Camp
KSKeisuke Sekine
Keisuke Sekine
TGTobias Gerber
Tobias Gerber
HLHenry Loeffler-Wirth
Henry Loeffler-Wirth
Hans BinderHans Binder
Hans Binder
BTBarbara Treutlein
Barbara Treutlein

1 August 2019 in Cell Metabolism
Verified
Journal Article
Closed access
RORie Ouchi
Rie Ouchi
STShodai Togo
Shodai Togo
MKMasaki Kimura
Masaki Kimura
TSTadahiro Shinozawa
Tadahiro Shinozawa
MKMasaru Koido
Masaru Koido
TTTakanori Takebe
Takanori Takebe

1 May 2015 in Cell Stem Cell
Verified
Journal Article
Closed access
TTTakanori Takebe
Takanori Takebe
MEMasahiro Enomura
Masahiro Enomura
EYEmi Yoshizawa
Emi Yoshizawa
MKMasaki Kimura
Masaki Kimura
HKHiroyuki Koike
Hiroyuki Koike
HTHideki Taniguchi
Hideki Taniguchi

7 June 2019 in Science
Verified
Journal Article
Closed access
PDF file
TTTakanori Takebe
Takanori Takebe
JWJames M. Wells
James M. Wells
Organoids are multicellular structures that can be derived from adult organs or pluripotent stem cells. Early versions of organoids range from simple epithelial structures to complex, disorganized tissues with large cellular diversity. The current challenge is to engineer cellular complexity into organoids in a controlled manner that results in organized assembly and acquisition of tissue function. These efforts have relied on studies of organ assembly during embryonic development and have resulted in the development of organoids with multilayer tissue complexity and higher-order functions. We discuss how the next generation of organoids can be designed by means of an engineering-based narrative design to control patterning, assembly, morphogenesis, growth, and function.

1 December 2017 in Cell Reports
Verified
Journal Article
Open access
TTTakanori Takebe
Takanori Takebe
KSKeisuke Sekine
Keisuke Sekine
MKMasaki Kimura
Masaki Kimura
EYEmi Yoshizawa
Emi Yoshizawa
SASatoru Ayano
Satoru Ayano
HTHideki Taniguchi
Hideki Taniguchi
Organoid technology provides a revolutionary paradigm toward therapy but has yet to be applied in humans, mainly because of reproducibility and scalability challenges. Here, we overcome these limitations by evolving a scalable organ bud production platform entirely from human induced pluripotent stem cells (iPSC). By conducting massive "reverse" screen experiments, we identified three progenitor populations that can effectively generate liver buds in a highly reproducible manner: hepatic endoderm, endothelium, and septum mesenchyme. Furthermore, we achieved human scalability by developing an omni-well-array culture platform for mass producing homogeneous and miniaturized liver buds on a clinically relevant large scale (>108). Vascularized and functional liver tissues generated entirely from iPSCs significantly improved subsequent hepatic functionalization potentiated by stage-matched developmental progenitor interactions, enabling functional rescue against acute liver failure via transplantation. Overall, our study provides a stringent manufacturing platform for multicellular organoid supply, thus facilitating clinical and pharmaceutical applications especially for the treatment of liver diseases through multi-industrial collaborations.